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ABSTRACT: The development of scaffolds with suitable physicochemical and mechanical properties allowing for the
structural regeneration of injured bone and recovery of the natural biological functionality is still a challenge in the tissue
engineering field. Nanostructured materials with added theranostic abilities, together with an interconnected hierarchy of pores,
offer the possibility to provide a new generation of bone implants. In this work, scaffolds with highly porous and resistant three-
dimensional structures have been successfully developed by homogeneously embedding mesoporous silica nanostructures in a
bioactive matrix of chitosan/κ-carrageenan. Moreover, magnetite (Fe3O4) nanoparticles were also added to the mesoporous
scaffold to include additional magnetic functionalities for diagnostic or therapeutic actions. The complete physicochemical
characterization shows mesoporous materials with a wide range of interconnected pores, remarkable surface roughness, and
large effective surface area, suitable for cell adhesion. In accordance to these properties, a simvastatin loading and release assay
showed high loading capacities and sustained release over a long period of time. Together with a suitable resistance against
degradation and biocompatible performance assessed by cell viability assays, these scaffolds show interesting features for
delivering drugs with activity in bone regeneration processes.
■ INTRODUCTION
Bone tissue defects caused by trauma, injuries, tumors,
congenital deformities, and diseases often result in a surgical
intervention and, in most cases, require the use of a type of
bone graft when these are large enough or critical-sized.1,2 The
development of biomaterials capable of providing bone tissue
regeneration and the recovery their biological functionality are
becoming an area of growing interest to improve life quality of
patients.3,4 In this context, highly porous biocompatible
scaffolds are intensively studied because of their ability to
guide the growth of new tissue and stimulate specific cellular
responses at molecular level.5 Specifically, hybrid scaffolds
composed of organic and inorganic biomaterials present the
advantage of combining a balanced set of properties such as
degradability and mechanical strength or flexibility and
cohesion, to improve their biological functions.6,7 From the
list of bioactive and resorbable biopolymers used in tissue
engineering, chitosan8,9 is at the forefront of many
pharmaceutical formulations for accelerated wound healing
because of its antibacterial, haemostatic, and mucoadhesive
power. In combination with the right amount of κ-
carrageenan,10 a negatively charged hydrophilic polysaccharide
capable of forming high-strength elastic hydrogels, a porous
scaffold can be obtained with a geometrically intricate
architecture11 that facilitates the formation of biosimilar
grafts.12
Further incorporation of an inorganic phase to the polymeric
matrix such as mesoporous silica material provides new
functionalities that improve the overall performance to
optimize the cellular scaffolding.13 Ordered mesoporous silica
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are known as third-generation biomaterials14 that combine
chemical, thermal, and mechanical stability, a hexagonal
arrangement of pore channels (SBA-15-type mesoporous
silica) together with a large and versatile surface that can be
easily functionalized by silanol chemistry.15,16 These materials
are capable of loading large amounts of therapeutically relevant
molecules such as peptides, enzymes, growth factors, antibod-
ies, or genetic components17 and provide local and steady
release.18 Moreover, nanosized mesoporous particles can be
conjugated to antibodies19 or functionalized with a fluorescent
moiety20 to be used in specific cell targeting or cell labeling
applications. When, in addition, magnetite (Fe3O4) nano-
particles (NPs) are incorporated to produce magnetic
mesoporous nanocomposites (SBA-15@Fe3O4), magnetic
functionalities are added to the three-dimensional (3D)
scaffolds. Magnetic doping provides synergistic effects such
as bone regeneration through magnetic stimulation or adds
theragnostic abilities such as MRI21 or magnetic hyper-
thermia.22 Recent innovations in bone tissue engineering
have shown that magnetic scaffolds in combination with static
magnetic fields are capable to improve bone cell migration,
adhesion, proliferation, and growth.23,24
Finally, an appropriate drug selection can provide important
therapeutic benefits when it is slowly released for a prolonged
period from the scaffold. According to this, simvastatin is a
popular cholesterol-lowering statin that has demonstrated
positive effects in the bone regeneration process,25−27
increasing the synthesis of bone morphogenetic protein 2
which is responsible for new bone formation, stimulating
osteoblast proliferation, differentiation, and maturation.28 Its
participation in osteocalcin production and bone mass
increase29,30 has a bone protect effect, reducing fracture risk.
In this work, we have developed 3D mesoporous scaffolds by
homogeneously blending an adequate proportion of inorganic
mesoporous silica nanostructures (SBA-15 type) with a
mixture of resorbable and bioactive natural polysaccharides,
chitosan/κ-carrageenan, using a simple mixing and processing
technique. The so-obtained structures were submitted to
structural, morphological, and textural characterizations,
showing a high degree of porosity with a random arrangement
of voids, resistance to degradation, and capacity of loading
large amounts of simvastatin together with a sustained and
prolonged release for nearly 2 months.
Biocompatibility was assessed by WST-1 and neutral red
cytotoxicity tests showing no toxic response, for plain scaffolds,
whereas simvastatin-loaded materials showed an enhanced cell
proliferation.
■ MATERIALS AND METHODS
κ-Carrageenan (Gelcarin GP 812NF) was supplied by IMCD;
chitosan (high molecular weight, deacetylated chitin) was
provided by Sinochem Quingdao Co. Ltd.; hydroxyapatite was
supplied by Fluka; 1,4-butanediol diglycidyl ether cross-linker
(BDDE, >95%) and acetic acid (glacial, CH3CO2H ≥ 99.85%)
were obtained from Aldrich; and simvastatin was obtained
from Fagron Iberica. Milli-Q (Merck-Millipore) deionized
water was used in all of the experiments. The other chemicals
used in our experiments were of analytical reagent grade
(supplied by Aldrich) and were used without further
purification.
Preparation of 3D Scaffolds (κ-Carrageenan-Chito-
san/SBA-15-Fe3O4). The development of a new generation of
highly porous 3D mesoporous scaffolds was obtained by
designing a facile method that allows generating a bioactive
and stable microstructure that can favor cell colonization,
adhesion, and growth as briefly described in the scheme of
Figure 1. In this regard, 100 mg of κ-carrageenan was dissolved
in 5 mL of deionized water at 70 °C under vigorous magnetic
stirring, to form a viscous gel. On the other hand, a second
dispersion was prepared by dissolving 300 mg of chitosan in 5
Figure 1. Synthesis of the 3D hybrid mesoporous scaffolds. A solution of κ-carrageenan in water (A) is added to a slightly acidic solution containing
chitosan and SBA-15 mesoporous silica nanostructures (B) and blended at 24 000 rpm for homogenization. Next, BDDE is added under
continuous blending, and this homogenized mixture is poured within a 10 mL syringe and kept at −20 °C for 24 h. Afterward, the cross-linking
reaction is carried out by demolding the cylinder into a basic KCl solution at 60 °C for 24 h. Finally, the sample is washed with water and freeze-
dried.
Table 1. Description of the Developed Scaffold Samples, Names (First Raw), and Their Mesoporous Silica Materials Content
(from Second to Last Raws)
sample formula SBMa characteristics synthesis method refs
Sc1 SBA-15 S15 ordered mesoporous silica soft template 31
Sc2 SBA-15/Fe3O4@SiO2
b LMNC low magnetic content nanocomposite microemulsion 22
Sc3 SBA-15/Fe3O4@SiO2
b HMNC high magnetic content nanocomposite microemulsion 22
Sc4 SBA-15/Fe3O4@PAA
c S15MPAA magnetic mesoporous nanocomposite coprecipitation 31
aSilica-based materials that are included the magnetic mesoporous nanocomposites. bMagnetite NPs Fe3O4 attached to the external SBA-15 surface
by covering with a silica SiO2 ultrathin layering.
cMagnetite NPs functionalized with polyacrylic acid synthesized in situ in the presence of the SBA-
15 material.
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mL of a slightly acidic solution, followed by the addition of 340
mg of the corresponding SBA-15-based material (Table 1),
which was incorporated by strong manual stirring. The SBA-
15-based materials were previously synthesized and reported
by Vargas-Osorio et al.22,31 The κ-carrageenan solution was
poured into the chitosan/mesoporous silica dispersion. The
new mixture was blended with an Ultra Turrax T25 at 24 000
rpm until a homogeneous dispersion was observed. Then, 0.4
mL of BDDE was added as a cross-linking agent and blended
again.
To form a cylindrical scaffold, the homogeneous mixture was
deposited inside a 10 mL syringe and then introduced into a
freezer at −20 °C. Once frozen, the scaffold was demolded and
immersed in a basic solution of potassium chloride (1% w/v)
at 50−60 °C for 24 h to achieve cross-linking. After this time,
the scaffold was washed with distilled water and lyophilized to
obtain the final product.
Morphological and Microstructural Characterization.
The morphology of the scaffolds was characterized by scanning
electron microscopy (SEM) using a Zeiss FE-SEM ULTRA
Plus microscope, employing secondary electrons and operating
at 5 kV. The microporosity of the scaffolds was analyzed by
mercury intrusion porosimetry (MIP) in a Micromeritics’
Autopore IV (Norcross GA, USA) using a 3 mL powder
penetrometer, with working pressures in the 0.004−172.4 MPa
range and an approximate weight of the samples of 0.25 g. Pore
size distributions were employed to model and simulate the
scaffolds’ porous structure by using the PoreXpert 1.3 software
(Environmental and Fluid Modelling Group, University of
Plymouth, UK). Mesoporosity and specific surface area were
estimated from N2 sorption isotherms obtained from a
Micromeritics ASAP 2000 instrument. Finally, the functional
groups present in 3D scaffolds were identified by Fourier
transform infrared spectroscopy (FTIR) in a Thermo Nicolet
Nexus spectrophotometer using the attenuated total reflec-
tance method.
Simvastatin Loading and Release Study. Scaffolds with
diameter Ø = 1 cm and mass 100 ± 10 mg were immersed in
10 mL of a water/ethanol simvastatin solution (3 mg/mL).
Simvastatin loading was carried out by incubating them at
room temperature for 24 h under dark conditions. After that,
the remaining solution was separated from the simvastatin-
loaded scaffolds and they were carefully dried and frozen at
−20 °C for 24 h. Before lyophilization, they were completely
frozen using liquid nitrogen at −195.8 °C. The release study
was performed using an incubator with an orbital shaker IKA
KS 4000ic at 37 °C and 100 rpm. The simvastatin-loaded
cylinders were immersed in a vial containing 4 mL of
phosphate buffer (pH = 7.4) and kept under physiological
conditions. At predetermined time intervals, the entire solution
was withdrawn and immediately replaced with an equal volume
of fresh soaking medium, maintaining the volume constant.
The amount of simvastatin released was monitored by UV/vis
spectrophotometry, measuring the absorbance values at the
wavelength of 239 nm, which is the wavelength of maximum
absorption for simvastatin. A standard calibration curve
(absorbance vs concentration) at different concentrations of
free simvastatin in phosphate-buffered saline (PBS) was
previously performed for this purpose. The simvastatin
absorbance profiles obtained both to generate the standard
curve and to know the concentrations released from each
scaffold corroborated that simvastatin kept its properties after
lyophilization because no difference between patterns was
observed.
Drug release profiles were fitted to a biphasic first-order
kinetic model. In this model, the initial fast release phase is
described by a first-order process related to the dissolution of
the drug adsorbed in the surface of the macropores. The
second release phase is also governed by a first-order
desorption kinetics associated with the drug released from
pores of the mesoporous silica materials. The total fitting
equation is
= − + − −− −F F F(1 e ) (1 )(1 e )k t k tB B1 2
where F is the total fraction of drug released at time t, FB is the
fraction of drug released in the first phase, k1 is the release rate
constant of the initial phase, and k2 is the release rate constant
of the second phase. A nonlinear least-squares regression
method was used to fit the release data to the model equations
using GraphPad Prism version 6.00 for Windows, GraphPad
Software, San Diego, California, USA. To determine the
concentration of simvastatin-loaded, it was necessary to carry
out the release assay until no absorbance was observed.
Furthermore, the degradation resistance of the scaffolds was
indirectly studied by keeping them in PBS under physiological
conditions until reaching 1500 h.
Cell Culture and Treatments. Mouse macrophage cell
line RAW 264.7 was obtained from ECACC (UK). Macro-
phages were cultivated in Dulbecco’s modified Eagle’s medium
(DMEM, Sigma-Aldrich, Spain), supplemented with 10% of
inactivated fetal bovine serum (FBS) and 1% of antibiotic/
antimycotic mixture consisting of 10 000 units/mL penicillin
and 10 000 units/mL streptomycin in 0.85% saline (Chemicon
International). Macrophages were cultured in a humidified 5%
CO2 atmosphere at 37 °C.
Preparation of Extracts. Disk specimens from scaffolds
were weighted (200 mg; 1 cm diameter) and kept for
incubation during 1, 7, and 14 days in a complete fresh cell
culture medium (DMEM, supplemented with mM L-
glutamine, 100 units/mL of penicillin, 100 mg/mL of
streptomycin, and 10% FBS; 10 mL) for extraction in the
cell incubator at 37 °C. After predetermined periods of time,
extraction medium samples were filtered (sterile filter 0.22 μm,
Millipore) and triplicate cultures were seeded in 96-well plates.
Cells were maintained for 24 h for each treatment and then
prepared for the cell proliferation assays.
Cell Proliferation Assay. Scaffolds’ cytocompatibility was
evaluated by two standard methods: the WST-1 assay and
neutral red uptake test. For the WST-1 assay, cells were seeded
in 96-well plates at a density of 15 000 cells/well in DMEM
supplemented with 10% FBS and left overnight for attachment.
Cell proliferation was determined using the WST-1 reagent
(Roche Diagnostics) according to the manufacturer’s protocol.
The neutral red uptake test was performed as follows:
neutral red stock solution of 40 μg/mL was added to cell
culture (10 000 cells/well) in 96-well plates overnight. A
destain solution for neutral red (50% ethanol/49% deionized
water/1% glacial acetic acid) was used. For quantifying the
extracted neutral red, a calibration curve was included in each
experiment.
The mean absorbance and standard deviation of three
replicates containing the same extract from each scaffold were
calculated and expressed as percentage of the absorbance
obtained for the control wells (nontreated cells), considered as
100% if cell viability. A concentration of 10% sodium dodecyl
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sulfate was used as negative control wells. Furthermore, the
same assays were also performed only with simvastatin in
solutions at 1, 10, 30, 50, and 100 μM. For better comparison,
the cell viability results were rated relative to controls as: not
cytotoxic (>90% viability), slightly cytotoxic (60−90% cell
viability), moderately cytotoxic (30−59% cell viability), and
strongly cytotoxic (<30% cell viability).32
Statistical Analysis. Data were expressed as mean ±
standard deviation (triplicate samples). Statistical analysis was
carried out using Student’s two-tailed t-test. A p-value of <0.05
was considered to be statistically significant.
■ RESULTS AND DISCUSSION
The selection of chitosan and κ-carrageenan mixed with
inorganic mesoporous silica matrices as components to
develop a resistant biocompatible 3D porous microstructure
is based on their chemical features that allow them to interact
strongly. On one hand, the amines of chitosan behave as a
reactive cationic polyelectrolyte with high charge density below
pH 6.5,33 easily adhering to the negatively charged κ-
carrageenan molecules,34 providing a high degree of mixing
of both biopolymers. On the other hand, the additional
incorporation of a cross-linker agent (BDDE) to the scaffold
formulation and their submission to a basic-saline environment
at 60 °C complete the covalent linking of the whole structure
by ionic gelation, improving their stability and resistance, as
was explained by De Boulle et al.35 Additionally, another
contribution to the porosity of these scaffolds arises during the
freezing stage process in which small ice crystals are created
that, on their turn, produce voids during the subsequent
sublimation of the primary drying phase. The presence of
mesoporous silica matrices inside the biopolymer structure
further interferes with the ice crystal formation, contributing to
the wide size range of porosity obtained.
The porous nature of the 3D hybrid mesoporous scaffolds is
shown in Figure 2A,B. In Figure 2A, a frontal view of a scaffold
shows that the cylindrical shape is preserved after the
Figure 2. (A) Frontal view of a scaffold picture evidencing the wide range of porosity sizes observable at macroscopic length. (B) Upper raw
corresponds to dried samples of mesoporous silica nanostructures doped with magnetite NPs; from right to left, samples color reflects the amount
of magnetic NPs doping [(a) high amount of doping S15MPAA, (b) medium doping LMNC, and (c) nondoped S15]. Bottom raw corresponds to
the 3D hybrid mesoporous scaffolds prepared by mixing the mesoporous silica immediately above them, from right to left: in a Sc4-bottom is
prepared with S15MPAA, in (b) a Sc2-bottom is prepared with to LMNC, and (c) to Sc1-bottom is prepared with S15. (C) Magnetic response of
the Sc2 cylinder in water under the action of an external neodymium iron boron permanent magnet.
Figure 3. SEM micrographs at different magnification scales (100; 20; and 2 μm) of 3D hybrid mesoporous scaffolds (A) Sc1, (B) Sc2, (C) Sc3,
and (D) Sc4, all evidencing the wide size range of pores in all of the prepared samples.
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demolding process and that the arrangement of pores is
completely random. In Figure 2B, the upper raw corresponds
to dried samples of mesoporous silica nanostructures doped
with magnetite NPs; from right to left, samples color reflects
the amount of magnetic NPs doping [(a) dark brown sample
has a high amount of doping S15MPAA, (b) light-orange has a
medium amount of doping LMNC, and (c) nondoped S15H].
In Figure 2B, the bottom raw corresponds to the 3D hybrid
mesoporous scaffolds prepared mixing with the mesoporous
silica immediately above them, from right to left: in (a) Sc4-
bottom is prepared with S15MPAA, in (b) Sc2-bottom is
prepared with LMNC, and (c) Sc1-bottom is prepared with
S15H.
The color matching between the magnetically doped silica
matrices and their scaffolds is due to the chemical stability of
the covalent linking between magnetite NPs and mesoporous
silica surface (SBA-15@Fe3O4) in accordance to prior studies
reported by our group.22 In Figure 2C, a magnetic scaffold
sample (Sc2) cylinder, in water, is strongly attracted to the
action of an external neodymium iron boron permanent
magnet. It can be noticed that despite the sharp movement of
the scaffold, the aqueous medium remains transparent and no
leaching of magnetite NPs can be observed (Figure 2B).
The microstructure and morphology of the scaffolds were
analyzed by SEM microscopy. Figure 3 shows highly porous
hierarchical structures with a remarkable surface roughness and
intricate pore walls. This special surface topography is given by
the presence of the SBA-15-based material, which is uniformly
distributed throughout the bioactive matrix. This silica
component also contributed to generating pores with different
morphologies and sizes, ranging from microns to nanometers
and to creating a significantly interconnected structure. In this
regard, the effects caused by this topography could have critical
implications in bone regeneration, enhancing cellular func-
tion,36 and increasing the initial attachment and seeding
efficiency.37
High-magnification SEM images of Figure 4 display the
interaction between the inorganic particles and organic phase.
These particles are partially embedded by a polysaccharide
film, which keeps them well integrated to the chitosan/
carrageenan matrix. These images also evidenced the existence
of a large interparticle porosity associated with pores of small
sizes. Pores <3 μm can improve cell−surface interaction and
anchorage-dependent cell−cell communication, as Bruzǎus-
kaite ̇ et al.38 reported.
To precisely determine the different phases that constitute
the 3D hybrid mesoporous scaffolds, a representative sample
(Sc3) was analyzed by energy-dispersive system (EDS)
mapping. Figure 5 shows two types of surface conformation,
one enriched with magnetic SBA-15 mesoporous silica that
increases and modifies the surface topography, making it
irregular and intricate, and another flatter and smoother that
corresponds to the chitosan/carrageenan matrix. By EDS
mapping, the location of each chemical element along the
scaffold can be identified, corroborating that the surface
roughness is intimately related to the presence of rod-like
mesoporous silica particles. Overall, the presence of carbon
(C) and oxygen (O), main components of the polysaccharides,
confirms that the organic part is the main constituent of the
network. On the other hand, iron (Fe) from magnetite NPs
appears in the same region as silica (Si), meaning that the
magnetic mesoporous silica nanocomposite maintains its
integrity during the scaffold production. In addition, sulfur
(S), present in the linear sulfated κ-carrageenan, is mainly
located in the same region where Fe appears, suggesting an
intense interaction between magnetic nanocomposite
(HMNC) and the polysaccharide.
The porous nature of the 3D mesoporous scaffolds was
characterized by MIP and nitrogen sorption isotherms
employing the Brunauer−Emmett−Teller (BET) and Bar-
rett−Joyner−Halenda (BJH) methods. Their pore size
distributions ranging from <0.1 to 200 μm are shown in
Figure 6A. The addition of SBA-15-based materials played a
crucial role in modifying the final features of the scaffolds.
Comparing them to two scaffolds previously synthesized by
Otero’s group39,40 from the same polysaccharide mixture one
without any nanocomposite (ScPM) and another using
hydroxyapatite (ScHA) instead. Only macropores between
10 and 200 μm were observed for ScPM, whereas for ScHA
between 70 and 200 μm. Besides, both samples exhibited a low
pore volume capacity. According to this, 3D hybrid
mesoporous scaffolds display a significantly higher perform-
ance. Furthermore, these hybrid matrices also showed porosity
at mesoscale. Thus, type IV isotherms with parallel adsorption
and desorption branches associated with a type H1 hysteresis
loop characteristic of the mesoporous materials with open
cylindrical pores are displayed in Figure 6B. The pore diameter
was calculated by the BJH method as is shown in Figure 6C,
whose values are displayed in Table 2, exhibiting narrow pore
size distributions with average pore sizes between 8 and 13 nm.
A detailed structural analysis of the scaffolds was performed
by PoreXpert software using the experimental information
obtained from MIP to calculate and create models with
percolation characteristics similar to the studied materials.
These models are represented by cubic structures, where the
cubes correspond to pores and the cylinders to interconnec-
Figure 4. SEM micrographs of the 3D hybrid mesoporous scaffolds
focused on locations where the embedded mesoporous silica
nanostructures are clearly visible (A) Sc1, (B) Sc2, (C) Sc3, (D)
Sc4, and (E) large magnification (200 nm) of a representative
example that highlight the interaction between a SBA-15-based
material and the chitosan/carrageenan phase, where some meso-
porous particles are totally covered by the polymeric film.
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tions. Table 2 compiles the estimated values of the hybrid
mesoporous scaffolds; these results agree with those observed
in SEM regarding highly porous and interconnected structures.
These scaffolds possess a great capacity to absorb fluids
without distorting their structure. Moreover, hybrid meso-
porous scaffolds are partially ordered structures that are built
up by disordered macropores and ordered mesopores. The
previously obtained correlation levels and connectivity values
of the ScHA and ScPM scaffolds below 0.01 and 2.6,
respectively, demonstrated the presence of completely
disordered and less interconnected porous structures. Figure
7 presents the 3D models generated by PoreXpert software of
Figure 5. (A) SEM image, (B) EDS spectrum, and element mapping images for (C) C (red), (D) O (blue), (E) Si (yellow), (F) Fe (green), and
(G) S (white) of the Sc3 hybrid mesoporous scaffold. The light blue line indicates an apparent separation between two different types of surfaces.
(For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).
Figure 6. (A) Pore size distributions obtained from MIP of the 3D hybrid mesoporous scaffolds and the scaffolds previously synthesized by Otero’s
group,39,40 (B) N2 sorption isotherms analyzed by BET, and (C) pore size distributions calculated by the BJH method of the 3D hybrid
mesoporous scaffolds.
Table 2. Textural Values Obtained From N2 Sorption and MIP by Using the PoreXpert Software of the 3D Mesoporous
Scaffolds
N2 sorption MIP
a
samples
SBET
(m2 g−1)
Vp
(cm3g−1)
DBJH
(nm)
porosity
(%) connectivity
correlation
level
permeability
(mD) tortuosity
fluids absorption in 0.01 s
(vol %)
Sc1 145.68 0.3080 8.46 83.77 3.90 0.161 2332.03 1.4 50.12
Sc2 80.10 0.2606 13.01 81.01 3.47 0.176 1882.39 1.6 56.81
Sc3 77.33 0.2403 12.43 81.52 3.80 0.262 980.20 1.6 58.82
Sc4 76.76 0.2085 10.87 78.96 5.82 0.166 3187.65 1.3 38.50
aThe porosity percent is a direct measure of the fraction of void spaces volume over the scaffolds total volume. Connectivity refers to the number of
pore channels connected to a node of the pore network. Correlation level determines the structural order or disorder of the pores (1 = high ordered
porous structure and 0 = random distribution of the pores). Permeability is the ability to allow a fluid to cross the material without altering its
internal structure. Tortuosity is a measure of the geometric complexity of a porous medium. The fluids absorption represents the volume
percentage that has been filled with water after 0.01 s of being in contact with an aqueous fluid media.
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the Sc1 scaffold and, additionally, the 3D model of the ScHA
scaffold as the best previously synthesized sample.
Simvastatin Loading and Release Assay. The scaffolds
were analyzed by FTIR to corroborate the adsorption of
simvastatin. The spectra of two representative bare- and
simvastatin-loaded scaffolds (Sc3, Sc4) are shown in Figure 8A,
together with the characteristic pattern42 of pure simvastatin
for comparison purposes. It can be observed that in the loaded
scaffold pattern, some of the characteristic peaks of simvastatin
appear overlapped on the pattern of bare scaffolds. Specifically,
this overlapping is evident through the intensification of
asymmetric and symmetric C−H stretching bands and C−H
bending vibrations at 2935 and 2872 cm−1 and at 1460 and
1370 cm−1, respectively. However, the clearest signature of
simvastatin presence is that associated with a high-intensity
stretching vibration at 1709 cm−1, corresponding to carbonyl
functional groups, followed by a slight intense O−H
deformation vibration, observed at 1250 cm−1, and a small
absorption band at 1158 cm−1 is assigned to the C−O
stretching mode.
Figure 7. Cubic models created by PoreXpert software, showing the Sc1 scaffold features. (A) Almost perfect cube, which represents an extremely
porous and interconnected structure, (B) volume of water capable of being absorbed per 0.01 s, and (C) simulation of bone cell migration by
spreading spherical particles with diameters between 10 and 30 μm, equivalent to bone cells (i.e., osteocytes with 7 μm of width and depth, and 15
μm of length),41 through the scaffold, where only a few particles with sizes higher than 20 μm remain trapped. (D) Porosity of the ScHA scaffold.
Figure 8. (A) FTIR spectra of simvastatin, loaded simvastatin, and plain mesoporous scaffolds, (B) simvastatin release profiles of the 3D hybrid
mesoporous scaffolds, where lines represent the fitting models of the biphasic first-order kinetics, TEM micrographs of the 3D hybrid mesoporous
scaffolds, where (C) corresponds to Sc1, (D) to Sc2, (E) Sc3, (F) Sc4, and (G) an example that best represent the interaction between organic and
inorganic components (Sc4 scaffold), (H) linear relationship between connectivity and FB, and (I) linear relationship between porosity and k2.
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The simvastatin loading capacity and efficiency of the 3D
hybrid mesoporous scaffolds are shown in Table 3. The
simvastatin release profiles of Figure 8B display a biphasic
behavior, which is related to a faster release rate during the first
9 h followed by a second stage governed by a much slower
kinetics associated with a sustained release process. The
second stage was performed over a long period, lasting
between 700 and 1400 h. In this regard, the release profiles
were perfectly fitted to a biphasic first-order kinetic model,
obtaining coefficients of determination higher than 99.5%. The
significant initial burst effect corresponded to the fast
simvastatin dissolution and diffusion from macropores. This
relatively fast release is supported by values of k1 significantly
higher than k2, which agrees with the model proposed by
Gallagher and Corrigan43 for biodegradable drug delivery
systems with an initial burst release. In contrast, the second
release profile was controlled by a first-order kinetics
associated with simvastatin desorption from mesopores,
whose presence is evidenced by transmission electron
microscopy (TEM) microscopy. Figure 8C−F reveals the
presence of different SBA-15-based materials, which have an
ordered mesoporous channel system and the attachment of
magnetite NPs to the SBA-15 surface for the magnetic
nanocomposites. Figure 8G best illustrates the interaction
between rodlike particles and the bioactive polysaccharide
matrix. In this regard, S15MPAA particles are completely
embedded in the chitosan/κ-carrageenan mixture, forming a
single system where all components are consistently integrated.
On the other hand, linear correlations between some
parameters were obtained. Figure 7C,D shows that an increase
in connectivity is directly proportional to an increase in the
percentage of simvastatin released during the first stage (FB),
whereas an increase in porosity produces a decrease in the
second release constant (k2). Thus, the release magnitude in
the first stage depended on connectivity by facilitating drug
diffusion, as well as a higher porosity allowed a better control
over drug kinetics, where the pore size distribution is an
important factor.
In addition, the differences in the release profiles are also
associated with the lipophilic nature of simvastatin; thereby,
the intermolecular interactions between the simvastatin and
functional groups were stronger in those SBA-15 mesoporous
silica nanostructures with a relatively hydrophobic surface such
as Sc1, Sc2, and Sc3, which possess silanol groups (Si−OH),
being Sc1 the sample with clearly the largest surface area.
Furthermore, different magnetic mesoporous nanocomposites
were employed for the synthesis of Sc2 and Sc3, where Sc3 has
a higher amount of magnetite NPs incorporated, which could
have increased the hydrophobicity in the medium. Therefore,
Sc1 and Sc3 loaded the highest amount of simvastatin and
present the slowest k2 release constants and the most sustained
releases.
In general, the use of mesoporous silica has drastically
increased the loading capacity of the scaffolds, allowing them
to adsorb large amounts of simvastatin compared to others.
For example, the previously prepared ScHA scaffold39,40 was
loaded with ciprofloxacin instead of simvastatin, loading less
than 7 mg g−1 and completely releasing it in 16 h. On the other
hand, the ScPM scaffold was not able to adsorb more than 4
mg g−1 simvastatin (unpublished data). The advantages of the
3D hybrid mesoporous scaffolds as powerful sustained delivery
systems were highlighted by comparing them with a recent
article published by Yu et al.44 related to a mesoporous
hydroxyapatite/collagen scaffold that enhanced osteogenesis
and angiogenesis by releasing simvastatin in a sustained way.
Yu et al. obtained a simvastatin loading efficiency of 7.6%
associated with a high loading concentration of 75.7 mg g−1
that was released over 500 h. In this regard, the results
presented in our study demonstrate higher loading efficiencies,
higher loading concentrations, and longer sustained delivery
processes of simvastatin.
Degradability. Scaffold cylinders were immersed in
simvastatin under physiological conditions (37 °C and 100
rpm) and kept for 1500 h, to test their stability in moisty
environment for 3−4 weeks. After this short-term degradability
test, mainly all scaffolds showed no morphological modifica-
tions or leakage of components. Previous 3D scaffolds based
on natural polymer mixtures synthesized in our group (data
not shown) with the aim of obtaining simultaneously good
mechanic performance and sustained delivery profile allowed
us to conclude that the absence of an inorganic component or
mineral material inhibited the improvement of mechanical
strength of the final formulations. On one hand, a mixture of
alginate, gelatin, and κ-carrageenan, cross-linked for 24 h in a
solution of CaCl2 (1.5%) and glutaraldehyde (2.5%) at pH 7,
was completely disintegrated in 48 h after having been
immersed in PBS buffer. The rapid disintegration of the
scaffold might be ascribed to an irregular and nonuniform
cross-linking of the polysaccharides and the ionization of the κ-
carrageenan and alginates at physiological pH causing the
swelling and disaggregation of the system. This evidenced that
mechanical performance of cross-linked alginate was worsened
by the mixture. A further incorporation of other aqueous
insoluble materials as zein, a hydrophobic vegetal protein that
forms resistant aqueous insoluble aggregates, or chitosan was
observed to slightly improve the mechanic properties without
being able to stop disintegration in short periods of time. As
Atila45 mentioned, natural polymers based on fibrous scaffolds
present an inadequate 3-dimensionality and poor mechanical
properties for their use as bone substitutes, despite having
excellent biocompatibility and bioactivity.
In fact, to overcome the lack of mechanical strength of
chitosan-based scaffolds, many approaches have been made by
combining chitosan with inorganic materials such as nano-
Table 3. Simvastatin Loading Capacity and Loading Efficiency and the Parameters Obtained by Fitting the Simvastatin Release
Profiles to a Biphasic First-Order Kinetic Modela
sample capacity (mg g−1) efficiency (%) Q9h (mg) FB (%) k1 (h
−1) k2 (h
−1) R2
Sc1 236.2 78.6 5.97 20.32 0.576 0.0019 0.9964
Sc2 187.8 62.6 4.06 18.47 1.098 0.0026 0.9950
Sc3 213.4 70.9 5.48 20.11 0.967 0.0019 0.9950
Sc4 196.1 65.3 8.22 35.70 0.698 0.0043 0.9956
aQ9h represents the amount of simvastatin delivered during the first 9 h; FB corresponds to the fraction of simvastatin released in the first phase; k1
and k2 are the first-order rate constants of the first and second delivery stages, respectively; and R
2 is the coefficient of determination.
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hydroxiapatite,46 silica,47 or different ceramics or mesoporous
silica,48,49 which may or may not include drugs or biofactors.
Conversely, κ-carrageenan has been scarcely used as a
biomaterial, although its advantages and similarities to natural
glycosaminoglycans present it as a candidate material to
produce composite scaffolds when combined with mineral
hydroxyapatite as bone substitutes.50,51
Thus, the incorporation of a SBA-15-based material to
polysaccharides formulation determined its stability, increasing
the mechanical properties of the hybrid scaffold. Figure 9
shows the appearance of the scaffolds after the assay was
concluded, the scaffolds kept their cylindrical shape, whereas
they were immersed in PBS, showing no signs of swelling.
However, when Sc2 was set aside from buffer, a slight
deformation associated with particle disaggregation was
evidenced. Stability can also be related to scaffold fabrication,
where a perfect homogenization of all constituents, avoiding
the formation of bubbles during pouring and molding process
is crucial. Finally, comparing the freeze-dried samples both the
originals and those after 1500 h (Figure 8C,D), a slight
contraction in all cases was observed, being the most radical
that concerning to Sc2. In general, the materials were easy to
handle and manipulate at any time, preserving between 90 and
80% of their original weight. Curiously, the scaffolds that
remained in optimal conditions were those that loaded the
highest amounts of simvastatin as is shown in Figure 8E.
Therefore, the interactions that take place on the surface
between the loaded molecules and functional groups of the
scaffolds through interparticle forces seemed to have deep
implications in the performance of these 3D hybrid structures.
The bone remodeling process is carried out by an equilibrium
between bone resorption produced by osteoclasts and bone
mineralization mediated by osteoblasts,52 which is initiated as
early as 3−4 weeks.53 Therefore, scaffolds so prepared by a
mixture of organic (chitosan and κ-carrageenan) and inorganic
(mesoporous silica nanostructures) form 3D bioactive and
stable structures that are suitable to be used as osseous
substitutes for bone tissue grafts.
Viability Assays. A preliminary screening of the bio-
compatibility was performed by using two different techniques
to assay the macrophage viability. Macrophages have been
demonstrated to have heightened sensibility to simvasta-
tin.54−56 The nonleaching components or degradation
products from implantable scaffolds are a primary concern in
regenerative medicine. Hence, we investigated the effects on
cell viability produced by incubating the macrophage cells with
the components released from highly porous scaffolds, which
were previously incubated in a cell culture medium for 1, 7,
and 14 days at 37 °C. The colorimetric assay (WST-1 based)
employs the dehydrogenase activity to measure the mitochon-
drial impairment that is highly correlated with cell prolifer-
ation. In this regard, cells cultured with fluid extracts from
Figure 9. Appearance of the 3D mesoporous scaffolds after 1500 h of being under physiological conditions (37 °C and 100 rpm) (A) immersed in
PBS, (B) outside PBS, (C) original lyophilized scaffolds, (D) final lyophilized samples, and (E) linear relationship between the percentage of the
remaining scaffold and simvastatin loading capacity.
Figure 10. WST-1 results of cell viability corresponding to the fluid extracts obtained (A) from plain scaffolds (no simvastatin), (B) from
simvastatin-loaded scaffolds, and (C) RAW 264.7 cell proliferation studies by WST-assay after incubation with simvastatin and pravastatin for 24 h.
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plain scaffolds (no simvastatin loaded) demonstrated that their
compatibility depended largely on the composition and
incubation time of the scaffolds as is observed in Figure 10A.
Thus, plain scaffolds showed excellent biocompatibility during
the first 7 days, which was moderately decreasing over time,
ranging between 73 and 61% (slightly cytotoxic) after 14 days
of incubation. Therefore, the toxic effect increased as the
concentration of the leached products (cross-linking agent,
degradation products...) accumulated in the well. These results
are perfectly comprehensible if it is taken into consideration
the static conditions during cell culture assays, compared to the
dynamic conditions that allowed for refreshing medium of a
real scenario of a regenerative process.
The beneficial effect of simvastatin to promote bone
formation after local administration has been described,57−59
proving to be a promoter of osteoblastic activity;44 however, its
cytocompatibility properties depend strongly on the concen-
tration when this is administrated by topical injection.60 Thus,
it will be necessary to set a critical point to perform an
adequate simvastatin release profile in the site of action
because its optimal therapeutic threshold is not yet
determined. In this context, the effect of the simvastatin
released from 3D mesoporous scaffolds was also studied.
Simvastatin incorporated within the scaffolds had a strong
effect when was released to the culture medium, as is shown in
Figure 10B. Its presence increased the macrophages viability
over time, beyond 100% at 14 days of assay, on contrary to the
patterns displayed by nonloaded scaffolds. In vitro release
profiles showed that cells were exposed to a fast and an
accumulative simvastatin release for at least 24 h, causing a cell
proliferation inhibition. This simvastatin concentration was
estimated in the range between 10 and 30 μM. However, the
ability of the scaffolds to sustainably release simvastatin for a
long time allowed reversing the effect observed during the first
hours by increasing the viability after 7 days, except for Sc3
that showed an increase from the first day. Nevertheless, it
should be considered that the simvastatin release profiles in the
culture medium could greatly differ from those in PBS;
therefore, it will not necessarily be reproduced in a similar way
in another physiological medium or under other conditions.
To rule out the possibility that simvastatin has interfered
with the cell proliferation method, a biocompatibility study
using simvastatin and its soluble derivative pravastatin at
different concentrations (1, 5, 10, 30, 50, and 100 μM) was
also performed at exactly same conditions that previous
experiments. Wells containing simvastatin and culture medium
with no cells were used as a control. A dose-dependent effect
on cell viability was clearly observed for pravastatin (Figure
10C), showing a proliferating effect below 5 μM. This effect on
cell activity was inversely proportional to the drug concen-
tration; the lowest tested concentration seemed to activate the
growth of cells. The effect observed at high concentrations
might be related to a deteriorating effect on cells by
pravastatin, or just to its low solubility in the cell culture
medium (pH 7.2−7.4). For its part, simvastatin exhibited the
highest cell viability percentage at a concentration of 10 μM,
although it also presented a proliferative effect in all of the
studied concentrations, as was also observed in the simvastatin-
loaded scaffolds. Hence, simvastatin did not interfere with cell
proliferation at any investigated concentration. The observed
trends agree with that exposed by Park54 regarding the effects
of statins on bone growth promotion, where at low
concentrations, they exert a proliferating effect, whereas at
higher concentrations, the proliferation is inhibited. In our
study, the simvastatin released at low concentrations enhanced
the RAW 267.4 macrophages cell proliferation, as we
hypothesized and as other works previously showed.55,56
A neutral red assay was performed to complement the
information regarding cell compatibility of the scaffolds. The
results of the neutral red assay for both the plain and
simvastatin-loaded scaffolds are given in Figure 11. The
cytotoxicity of the 3D mesoporous scaffolds was expressed as
the percentage of viable cells compared to control cells
cultivated in a fresh medium. By testing the extracts recollected
from plain scaffolds, it was observed that the cytotoxicity
considerably increased for Sc1 and Sc2 at 14 days, and
according to the dehydrogenase assay, on the contrary, the Sc4
sample notably increased its viability, which could be
associated with the growing accumulation of leachable
compounds in the well. However, we found a linear
relationship at 14 days of assay between the magnetite content
and cell viability in those scaffolds made from a magnetic
mesoporous nanocomposite. Thus, the compatibility increased
directly proportional to the amount of magnetite present in the
sample as is shown in Figure 10C.
On the other hand, cells treated with fluid extracts obtained
from simvastatin-loaded scaffolds proved to be noncytotoxic. It
should be considered that nondynamic conditions of in vitro
cell culture might exacerbate the toxic effect because in an in
vivo situation, the physiological clearance would remarkably
Figure 11. Cell viability studied by neutral red assay for fluid extracts corresponding to (A) plain scaffolds, (B) simvastatin-loaded scaffolds, and
(C) linear relationship between the magnetite content and cell viability measured at 14 days of assay of the plain scaffolds.
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decrease the concentration of leachable products. Furthermore,
although not early toxicity was found in any case, viability
never reached 100%. According to neutral red assay, the
macrophage cytotoxic response was mainly restricted to the
differences between each scaffold such as surface functionality,
magnetite content, and probably, the magnetic NPs arrange-
ment in the employed nanocomposites.
There are a few reports available in the literature on the
cytocompatibility of the hybrid mesoporous materials with a
variety of chemical compositions, where different incubation
times and cell types were used.49,61,62 In this work, two
different assays have been used to evaluate the cell viability of
an immortalized cell-line of murine macrophages, where they
were cultivated with fluid extracts recollected from mesoporous
scaffolds. In other words, cell viability was evaluated according
to two different parameters: the metabolic activity by
measuring the enzymatic conversion of the tetrazolium salt
in the mitochondria, and the cell membrane integrity by
measuring the uptake of the neutral red by living cells. Overall,
the differences between both assays also depended on their
features and sensitivity even when the same cell line was tested.
In the WST-1 test, the increase in the mitochondrial
dehydrogenase activity when macrophages were in contact
with the simvastatin released from scaffolds, resulted in an
increase in the number of viable cells over time. In the neutral
red assay, the effect of a compound is localized in lysosomes,
without affecting the mitochondria.
Thus, the scaffolds for tissue regeneration must provide an
adequate environment for cell growth and proliferation. During
this remodeling process, an in vivo inflammatory response has
been usually observed. In this regard, RAW 264.7 cells are a
murine macrophage line that displays inflammatory features
similar to in vivo macrophages. Our in vitro results
demonstrated that the hybrid mesoporous scaffolds containing
simvastatin did not have an early cytotoxic reaction under the
conditions tested, contributing to the macrophage cell
proliferation. In addition, they displayed mechanical strength
and a low and prolonged degradation. Further studies should
be conducted in the future to explore the inflammatory
response in vitro and in animal models to consider these 3D
hybrid mesoporous scaffolds as therapeutic bone tissue
regeneration systems.
■ CONCLUSIONS
In the present work, highly porous 3D mesoporous scaffolds
were successfully developed by homogeneously combining
bioactive, biodegradable, and easily processable polysacchar-
ides with hybrid mesoporous silica materials. Morphological
and textural properties assessed with SEM, MIP, and BET
studies, including the values estimated by PoreXpert software.
The composite scaffolds have a large surface area because of
the presence of a vast number of interconnected pores of
different sizes with an enhanced surface roughness produced
by the presence of embedded mesoporous silica nanostruc-
tures. As a result of the surface chemistry and porosity of the
hybrid composition of the scaffolds, large amounts of water-
insoluble simvastatin were loaded in the structures, providing a
sustained release for long periods that exceeded 30 days.
Cytological tests did not show an adverse general response on
cell viability when cells were coincubated with fluid extracts
and plain scaffolds, and for simvastatin-loaded structures, a cell
proliferation effect was generated over time. The biocompat-
ibility and physicochemical properties of these scaffolds,
together with their prolonged release ability, make them
interesting materials for sustained release of lipophilic drugs
during the bone regeneration process.
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(38) Bruzǎuskaite,̇ I.; Bironaite,̇ D.; Bagdonas, E.; Bernotiene,̇ E.
Scaffolds and Cells for Tissue Regeneration: Different Scaffold Pore
Sizesdifferent Cell Effects. Cytotechnology 2016, 68, 355−369.
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